Humacyte, Inc.
HUMA
$1.29
$0.032.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 150.17% | -41.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 150.17% | -41.78% | |||
| Cost of Revenue | -21.09% | 42.75% | |||
| Gross Profit | 23.44% | -45.65% | |||
| SG&A Expenses | -2.55% | -4.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.27% | 26.70% | |||
| Operating Income | 17.95% | -28.22% | |||
| Income Before Tax | 53.50% | -196.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 53.50% | -196.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.50% | -196.22% | |||
| EBIT | 17.95% | -28.22% | |||
| EBITDA | 19.17% | -30.51% | |||
| EPS Basic | 54.35% | -181.64% | |||
| Normalized Basic EPS | 31.68% | -157.26% | |||
| EPS Diluted | 54.35% | -182.50% | |||
| Normalized Diluted EPS | 31.68% | -157.77% | |||
| Average Basic Shares Outstanding | 1.85% | 18.09% | |||
| Average Diluted Shares Outstanding | 1.85% | 17.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||